LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Aldeyra Therapeutics Inc

Închisă

2.65 8.16

Rezumat

Modificarea prețului

24h

Curent

Minim

2.62

Maxim

2.66

Indicatori cheie

By Trading Economics

Venit

5.9M

-9.9M

EPS

-0.17

Marjă de profit

-6,465.066

Angajați

8

EBITDA

5.9M

-9.4M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+280.82% upside

Dividende

By Dow Jones

Următoarele câștiguri

30 iul. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

-5M

127M

Deschiderea anterioară

-5.51

Închiderea anterioară

2.65

Scor tehnic

By Trading Central

Încredere

Very Strong Bearish Evidence

Aldeyra Therapeutics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

3 apr. 2025, 22:40 UTC

Principalele dinamici ale pieței

Aldeyra Shares Fall on FDA Complete Response Letter for Dry Eye Disease Drug

18 nov. 2024, 20:20 UTC

Principalele dinamici ale pieței

Aldeyra Therapeutics Shares Up, FDA to Review New Drug Application

Comparație

Modificare preț

Aldeyra Therapeutics Inc Așteptări

Obiectiv de preț

By TipRanks

280.82% sus

Prognoză pe 12 luni

Medie 9.33 USD  280.82%

Maxim 11 USD

Minim 6 USD

În baza a 6 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruAldeyra Therapeutics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

6 ratings

6

Cumpărare

0

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

1.9 / 2.65Suport & Rezistență

Termen scurt

Very Strong Bearish Evidence

Termen mediu

Very Strong Bearish Evidence

Termen lung

Strong Bearish Evidence

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Aldeyra Therapeutics Inc

Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases. The company also develops ADX-629, an orally administered RASP modulator for treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa, as well as rare retinal diseases characterized by inflammation and vision loss. In addition, it develops ADX-246 in systemic immune-mediated disease; and ADX-248 in geographic atrophy. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.